Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia

Laura S. Angelo and Razelle Kurzrock


Updated Version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-08-2791

Cited Articles
This article cites 13 articles, 6 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/4/1123.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia

Commentary on Ghosh et al., p. 1250

Laura S. Angelo and Razelle Kurzrock

In this issue of Clinical Cancer Research, Ghosh and coworkers (1) investigate, in the preclinical setting, a novel approach to treating B-chronic lymphocytic leukemia (B-CLL) that combines two naturally occurring compounds, curcumin and epigallocatechin-3-gallate (EGCG). Current treatments for B-CLL include purine analogues (fludarabine) and monoclonal antibodies (rituximab; ref. 2). Although people can live for years with B-CLL, there is no effective cure. Hence, new targeted therapies are vital to improving clinical outcomes for patients with B-CLL.

Using natural compounds for the treatment of cancer is not new. Sixty-two percent of cancer drugs approved by the U.S. Food and Drug Administration between 1981 and 2002 were of natural origin (3). For example, all-trans retinoic acid, which is a vitamin A derivative, is a very effective treatment for acute promyelocytic leukemia. A wealth of data supports a role for curcumin in many different cancers, including breast, prostate, head and neck squamous cell carcinoma, multiple myeloma, and pancreatic cancer (4–9). However, curcumin also inhibits the constitutive activation of pro-survival genes and angiogenic factors and is vital to various cytokine signaling pathways (4, 5, 11). STAT3 plays an important role in the induction of antiapoptotic genes and angiogenic factors and is vital to various cytokine signaling pathways (4, 5, 11). Curcumin effectively inhibits constitutive STAT3 phosphorylation in B-CLL (1), reflecting the activation of programmed cell death. PARP cleavage is induced by curcumin in other tumor types, including pancreatic and colorectal cancer (7–9).

Interestingly, the authors did not observe activation of upstream caspases following curcumin treatment. This differs from several other studies that show specific caspase-3 activation by curcumin in HL-60 and other tumor cell lines (4, 5, 10). In primary B-CLL, the mechanism of PARP cleavage remains unclear. Other cellular events that contribute to curcumin-induced apoptosis include the release of cytochrome c from the mitochondrial membrane. This occurs in different cell lines following treatment with curcumin, as do changes in mitochondrial membrane potential (4, 5).

Curcumin also inhibits the constitutive activation of pro-survival pathways, some of which are preferentially active in primary B-CLL cells, including STAT3, Akt, and NF-κB. Constitutive activation of STAT3 has been reported in several cancers, including breast, prostate, head and neck squamous cell carcinoma, multiple myeloma, and pancreatic cancer (4, 8, 11). STAT3 plays an important role in the induction of antiapoptotic genes and angiogenic factors and is vital to various cytokine signaling pathways (4, 5, 11). Curcumin effectively inhibits constitutive STAT3 phosphorylation in B-CLL (1), agreeing with other studies that show that curcumin is an effective inhibitor of STAT3 function (4, 5, 11). Mcl-1, a prosurvival gene downstream of STAT3, is also down-regulated by curcumin in primary B-CLL (1). Constitutive phosphorylation of Akt is down-regulated by curcumin in primary B-CLL cells (1) and other tumors, including non–Hodgkin’s B-cell lymphoma, prostate cancer, and renal cell carcinoma (4). However, curcumin can also induce its proapoptotic and antiproliferative effects without perturbing Akt phosphorylation status (5, 7, 12).

A prosurvival molecule that seems to be universally inhibited by curcumin is the NF-κB transcription factor. NF-κB is down-regulated by curcumin in many different cancers (4–8, 11).
Constitutive phosphorylation of IκBα in primary B-CLL cells is inhibited by curcumin, indicating that genes downstream of NF-κB should be inhibited in these cells. Indeed, XIAP, a downstream target of NF-κB, is down-regulated in primary B-CLL following curcumin treatment (1). The lack of down-regulation of Bcl-2 by curcumin is an interesting finding considering previous work showing that Bcl-2 is a direct transcriptional target of NF-κB and is down-regulated by curcumin (4, 5). BIM, a proapoptotic protein, is up-regulated by curcumin in primary B-CLL. Hence, curcumin can down-regulate survival pathways and up-regulate apoptotic pathways in B-CLL.

What happens to the effectiveness of curcumin treatment when B-CLL cells are cocultured in the context of the stromal environment? Stromal cells typically maintain an antiapoptotic environment through direct contact and through soluble mediators. Coculture of B-CLL cells with stromal cells provided substantial protection from curcumin-induced apoptosis at lower curcumin doses, but not at higher doses (20 μmol/L; ref. 1). These results lend insight into the effect of the host environment on curcumin-induced apoptosis and also indicate that higher therapeutic doses of curcumin may be required to achieve the level of apoptosis seen in vitro.

It is unlikely that curcumin alone will be an effective treatment for B-CLL due to incomplete apoptotic responses. Curcumin itself enhances the effectiveness of a variety of compounds, including vincristine, in B-CLL in vitro (6). Natural agents, such as curcumin, are desirable candidates for adjuncts to chemotherapy because of their negligible toxicities. EGCG, the principal polyphenol in green tea, induces apoptosis in B-CLL cells in vitro through partial inhibition of vascular endothelial cell growth factor receptor (VEGFR) 1 and VEGFR2 phosphorylation and also by caspase-3 activation and PARP cleavage. Bcl-2 is down-regulated by EGCG, as is Mcl-1 and XIAP (1). Treatment of primary B-CLL cells with the combination of EGCG and curcumin was investigated. The sequential administration of EGCG followed by curcumin was the most effective treatment combination, whereas simultaneous administration resulted in antagonistic effects.

EGCG and curcumin target many of the same molecular pathways, including induction of PARP cleavage and the inhibition of telomerase activity (1, 4, 5, 10). Although EGCG and curcumin down-regulate many common survival pathways, including STAT3, Akt, NF-κB, and the antiapoptotic genes Mcl-1 and XIAP, not all of their targets overlap (Fig. 1). For example, although both compounds induce PARP cleavage and apoptosis in B-CLL, EGCG accomplishes this through activation of caspase-3, whereas curcumin does not induce caspase-3 activation in these cells (1). Thus, these two natural agents have many pathways in common but can diverge from each other as well and can potentially exhibit opposing effects. Hence, further study of the molecular mechanisms involved in the antiproliferative and proapoptotic effects of these agents is warranted.

Clinical trials with curcumin and EGCG as individual agents, or in combination with standard chemotherapy, are already underway in several cancers (4, 5, 11). A phase II clinical trial of curcumin in advanced pancreatic cancer was recently published by our group and showed a patient with a 73% tumor regression and another patient who was stable on curcumin for more than 2.5 years (11). No side effects were observed. However, overall response rates were low perhaps because curcumin absorption after oral administration is poor (11).

Oral green tea extracts have been taken voluntarily by patients with B-CLL, and EGCG has already begun phase I clinical trials in Rai stage 0 to II patients with B-CLL (1). The current study provides rationale for the combination of curcumin plus EGCG in the clinical setting and provides information about the dose and administration of these two compounds. A constant ratio of 10:1 (EGCG/curcumin) was established as effective at inducing apoptosis in B-CLL. Sufficiently high doses of EGCG and of circulating curcumin...
will be necessary to overcome stromal protection in vivo. The data also indicate that sequential treatment of B-CLL with EGCG followed by curcumin is preferable to simultaneous treatment and is crucial to the efficacy of the combination of these two compounds. Simultaneous treatment of B-CLL cells with EGCG and curcumin resulted in antagonistic effects. Ultimately, however, the optimal studies will probably require the use of a curcumin compound modified to enhance its bioavailability. Encapsulating curcumin in liposomes allows it to be administered systemically, and several groups are working on altering curcumin to increase its absorption when taken orally (4, 5, 9, 13). Based on the biological properties of curcumin alone or in combination with EGCG or other compounds, these second-generation curcumin moieties should be explored for the treatment of CLL and other cancers.

Disclosure of Potential Conflicts of Interest

R. Kurzrock, ownership interest, patent filed for liposomal curcumin, SignPath.

References


DOI:10.1158/1078-0432.CCR-08-2791